FR2732215A1 - Skin-lightening cosmetic compsns. - Google Patents

Skin-lightening cosmetic compsns. Download PDF

Info

Publication number
FR2732215A1
FR2732215A1 FR9503760A FR9503760A FR2732215A1 FR 2732215 A1 FR2732215 A1 FR 2732215A1 FR 9503760 A FR9503760 A FR 9503760A FR 9503760 A FR9503760 A FR 9503760A FR 2732215 A1 FR2732215 A1 FR 2732215A1
Authority
FR
France
Prior art keywords
proteases
sep
cosmetic compositions
compositions according
keratolytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9503760A
Other languages
French (fr)
Other versions
FR2732215B1 (en
Inventor
Daniel Greff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sederma SA
Original Assignee
Sederma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sederma SA filed Critical Sederma SA
Priority to FR9503760A priority Critical patent/FR2732215B1/en
Publication of FR2732215A1 publication Critical patent/FR2732215A1/en
Application granted granted Critical
Publication of FR2732215B1 publication Critical patent/FR2732215B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

Cosmetic compsns. contg. at least one substance having skin depigmentation activity and keratolytic proteases, are new. Pref. the proteases are of plant or biotechnological origin. The compsns. contain skin lightening cpds. chosen from gluconic acid, glucosamine, calcium salt of pantothen sulphonic acid and/or a deriv. analogue or precursor of vitamin A, pref. beta -carotene. The proteases and the depigmenting substances are in the form of powder, paste, aq. dispersion, balm or oil. The proteases are used at doses of 0.1-20 units/g of cosmetic end prod. (pref. 1-10 units/g). The compsns. may be in any cosmetic from e.g. shampoos, scalp treatment prods. or make-up prods..

Description

La pigmentation de la peau est due à la synthèse de mélanine dans les cellules spécialisées, ainsi qu'à la distribution homogène de cette mélanine dans les kératinocytes de l'épiderme. Dans une peau saine, parfaite, cette synthèse est bien règlée, modulée par l'exposition au soleil et par le pucessus de désquamation.The pigmentation of the skin is due to the synthesis of melanin in the specialized cells, as well as to the homogeneous distribution of this melanin in the keratinocytes of the epidermis. In healthy, perfect skin, this synthesis is well regulated, modulated by exposure to the sun and the overdose of despondency.

II arrive, néanmoins, dans de nombreux cas que ce processus complexe est déréglé : un manque de mélanogénèse (soit dû à un problème génétique, soit à la suite d'une blessure de la peau) est aussi possible qu'une surabondance localisée de pigmentation : les tâches de rousseur, les tâches de sénescence, et les tâches diffuses (chloasma, tâches de grossesse) en sont les phénomènes les plus connus. It happens, however, in many cases that this complex process is disordered: a lack of melanogenesis (either due to a genetic problem, or as a result of a skin injury) is also possible that a localized superabundance of pigmentation Freckles, senescence tasks, and diffuse tasks (chloasma, pregnancy tasks) are the most well known phenomena.

Puisque ces symptômes ne constituent pas de véritables pathologies, étant plus un problème d'ésthetique que de santé, et puisque la méhnogénèse à lieu au sein de l'épiderme, c'est plutôt l'industrie cosmétique que celle de la pharmacie qui s'est intéressée à ce problème.Since these symptoms do not constitute true pathologies, being more a problem of aesthetics than of health, and since the mehnogenesis takes place within the epidermis, it is rather the cosmetic industry than that of the pharmacy which is is interested in this problem.

De nombreuses molécules ou substances ont été proposées pour traiter rlTyperpigmenSon de la peau, mais peuvent être retenues pour une application topique cosmétique (problème d'irritation, de législation, de toxicité). Ceux qui restent après cette sélection ne sont en général pas très eI5caces : I'hydroquinone synthétique (limitée à 2% dans les produits cosmétiques), la lutéoline extraite de certaines plantes, la vitamine C s'avèrent les plus utilisées sans que les effets soit très probants. Many molecules or substances have been proposed for treating skin hyperpigmentation, but may be selected for topical cosmetic application (irritation, legislation, toxicity). Those who remain after this selection are generally not very effective: Synthetic hydroquinone (limited to 2% in cosmetics), luteolin extracted from certain plants, vitamin C are the most used without the effects being very convincing.

Une des raisons de cet échec partiel pourrait être recherchée dans la biodisponibilité des molécules (manque de pénétration à travers la couche comée). Les mélanocytes se trouvent dans les couches moyennes de épiderme. One of the reasons for this partial failure could be sought in the bioavailability of molecules (lack of penetration through the comedic layer). Melanocytes are found in the middle layers of the epidermis.

L'objet du présent brevet est la découverte qu'il est possible de pallier à cet inconvénient en combinant la ou les substances intervenant dans rinhibition de la mélanogénèse avec des enzymes protéolytiques, kératolytiques qui pennettent, de façon douce, d'accélérer la desquamation et donc de briser la barrière presque infranchissable des couches supérieures de l'épiderme.The object of this patent is the discovery that it is possible to overcome this disadvantage by combining the substance or substances involved in the inhibition of melanogenesis with proteolytic enzymes, keratolytics which allow, in a gentle way, to accelerate the desquamation and to break the almost impassable barrier of the upper layers of the epidermis.

vautres substances kératolytiques peuvent être utilisées dans ce but, telles que les acides lactiques, glycoliques, salicyliques. Pour être efficaces, ces acides doivent être employés à des doses relativement élevées (S10%) ce qui a plusieurs inconvénients: fort potentiel d'irritation cutanée, pH des préparations très bas, difficultés de tormulation et de parfumage. other keratolytic substances may be used for this purpose, such as lactic, glycolic, salicylic acids. To be effective, these acids must be used at relatively high doses (S10%) which has several disadvantages: high potential for skin irritation, very low preparations pH, difficulty of formulation and perfume.

Les enzymes protéolytiques choisies dans le cadre de notre invention ne possèdent pas ces inconvénients. Le pH des produits peut respecter celui naturel de la peau (5-7), les émulsions ne sont pas perturbées, le parfumage est libre, et les doses actives d'enzyme ne provoquent ni iiatation ni sensibilisation.The proteolytic enzymes chosen in the context of our invention do not have these disadvantages. The pH of the products can respect the natural pH of the skin (5-7), the emulsions are not disturbed, the perfume is free, and the active doses of enzyme do not cause irritation or sensitization.

Alors que tout type de molécule dépigmentante peut être combinée avec les protéases kératolytiques, nous avons observé des effets particulièrement intéressants avec une préparation contenant de l'acide gluconique (en tant que chélsant de cuivre, privant ainsi, enzyme tyrosinase de son métal indispensable pour l'activité d'oxydation de la tyrosine), la glucosaine (inhibiteur puissant de la glycosylation de la tyrosinase, attaquant le processus en amont par rinhibition de l'activation de l'enzyme même), le sel calcique de l'acide pantothène sulfonique (PASS-Ca de la société
SOGO) et les dérivées, précurseurs ou analogues de la vitamine A, en particulier le B carotène. Ces molécules agissent soit seule, soit ensemble pour freiner la mélanogénèse. Leur activité est renforcée in vivo par l'adjonction d'enzymes kératolytiques.While any type of depigmenting molecule can be combined with keratolytic proteases, we have observed particularly interesting effects with a preparation containing gluconic acid (as a copper chelant, thus depriving the enzyme tyrosinase of its essential metal for tyrosine oxidation activity), glucosaine (a potent inhibitor of tyrosinase glycosylation, attacking the upstream process by inhibiting the activation of the enzyme itself), the calcium salt of pantothenesulphonic acid ( PASS-Ca of society
SOGO) and derivatives, precursors or analogues of vitamin A, especially B carotene. These molecules act either alone or together to slow down melanogenesis. Their activity is enhanced in vivo by the addition of keratolytic enzymes.

Les enzymes utilisées préférentiellement sont d'origine végétale (extraits de plantes: bromélaine, papaïne etc...) ou d'origine microbienne obtenues à l'échelle industrielle par fermentation biotechnologique (bacilus subis, aspergillus spp. etc...).The enzymes used preferentially are of plant origin (plant extracts: bromelain, papain, etc.) or of microbial origin obtained on an industrial scale by biotechnological fermentation (bacilus, aspergillus spp., Etc.).

L'activité dépigmentante d'une combinaison de substances inhibitrices de mélanogénèse avec les kératinases a été vérifiée dans un test sur volonlaires sains.The depigmenting activity of a combination of melanogenesis inhibiting substances with keratinases was verified in a healthy volunteers test.

On mesure la couleur de la peau à l'aide d'un Chromamètre (Minolta) pow relever les trois paramètres "clarté", composante "rouge" et composanle "jaune".The color of the skin is measured using a Chromameter (Minolta) to measure the three parameters "clarity", component "red" and component "yellow".

Les produits cosmétiques contenant les substances inhibitrices de mélanogénèse citées ci-dessus et une quantité suffisante de protéase, sont appliqués sur les taches d'hyperpigmentation (chloasma, mélasma) des vobrilaires pendant une période de 8 semaines. Les valeurs chromamétriques sont relevées après 4 et 8 semaines de traitement
A titre d'exemple, les crèmes suivantes ont été testées sur 30 personnes présentant les symptômes d'hyperpigmentation bcale.

Figure img00040001
Cosmetic products containing the melanogenesis inhibiting substances mentioned above and a sufficient amount of protease are applied to the hyperpigmentation spots (chloasma, melasma) of the vibrilaires for a period of 8 weeks. Chromametric values are found after 4 and 8 weeks of treatment
For example, the following creams have been tested on 30 people with symptoms of ovarian hyperpigmentation.
Figure img00040001

<tb><Tb>

<SEP> Crème <SEP> A <SEP> Crème <SEP> B <SEP> Crème <SEP> C <SEP>
<tb> Monostéarate <SEP> de <SEP> sorbitan <SEP> 2.00 <SEP> 2.00 <SEP> 2.00
<tb> Po-t > ate60 <SEP> 3.00 <SEP> 3.00 <SEP> 3.00
<tb> Abool <SEP> cétylique <SEP> 1.50 <SEP> 1.50 <SEP> 1.50
<tb> Pabmitate <SEP> d'isopropyle <SEP> 6.00 <SEP> 6.00 <SEP> 6.00
<tb> Huile <SEP> de <SEP> vaseline <SEP> 5.00 <SEP> 5.00 <SEP> 5.00
<tb> Cire <SEP> diabelles <SEP> 4.00 <SEP> 4.00 <SEP> 4.00
<tb> Propylène <SEP> glycol <SEP> 3.00 <SEP> 3.00 <SEP> 3.00
<tb> Acide <SEP> gluconique <SEP> 0.20 <SEP> 0.20
<tb> Glucosarnine <SEP> 0.20 <SEP> 0.20
<tb> Kérallnase200U* <SEP> 3.00
<tb> B <SEP> Carotène <SEP> 0,005 <SEP> 0,005
<tb> Lécitine <SEP> de <SEP> soja <SEP> 0,25 <SEP> 0,25
<tb> Eau <SEP> + <SEP> conservateur <SEP> qsp <SEP> 100 <SEP> qsp <SEP> 100 <SEP> qsp <SEP> 100 <SEP>
<tb>
U = mol. Tyrosine/min/ml
Après 4 semaines de traitement, on constate une différence de pigmentation sur les sites traits aux crèmes A et B par rapport à la crème C (placebo), après 8 semaines les trois sites se différencient nettement ('a clarté chromamétrique augmente de façon significative + 15% sur les sites traités à la crème A, contre +7% sur les sites traités à la crème B et 0.5% sur les sites placebo).<SEP> Cream <SEP> A <SEP> Cream <SEP> B <SEP> Cream <SEP> C <SEP>
<tb> Monostearate <SEP> of <SEP> sorbitan <SEP> 2.00 <SEP> 2.00 <SEP> 2.00
<tb>Po-t> ate60 <SEP> 3.00 <SE> 3.00 <SEP> 3.00
<tb> Abool <SEP> Cetyl <SEP> 1.50 <SEP> 1.50 <SEP> 1.50
<tb> Isopropyl Pabmitate <SEP><SEP> 6.00 <SEP> 6.00 <SEP> 6.00
<tb> Oil <SEP> of <SEP> Vaseline <SEP> 5.00 <SEP> 5.00 <SEP> 5.00
<tb> Wax <SEP> Diabetes <SEP> 4.00 <SEP> 4.00 <SEP> 4.00
<tb> Propylene <SEP> Glycol <SEP> 3.00 <SEP> 3.00 <SEP> 3.00
<tb><SEP> Gluconic acid <SEP> 0.20 <SEP> 0.20
<tb> Glucosamine <SEP> 0.20 <SEP> 0.20
<tb> Kérallnase200U * <SEP> 3.00
<tb> B <SEP> Carotene <SEP> 0.005 <SEP> 0.005
<tb> Lecitin <SEP> of <SEP> soya <SEP> 0.25 <SEP> 0.25
<tb> Water <SEP> + <SEP> preservative <SEP> qsp <SEP> 100 <SEP> qsp <SEP> 100 <SEP> qsp <SEP> 100 <SEP>
<Tb>
U = mol. Tyrosine / min / ml
After 4 weeks of treatment, there is a difference in pigmentation on the sites treated with creams A and B compared to cream C (placebo), after 8 weeks the three sites are clearly differentiated (chromammetric clarity increases significantly + 15% on sites treated with cream A, against + 7% on sites treated with cream B and 0.5% on placebo sites).

Les traitements sont bien tolérés par les volontaires.The treatments are well tolerated by the volunteers.

Pour être efficace, H convient d'utiliser des protéases kératolytiques stables, non irritantes et non sensibilisantes et de les employer à des doses adéquates, c'est-à-dire 0.1 à 20 Unités /g de produit cosmétique fini, prZrentiellement entre 1 et 10 Unités/g. To be effective, stable, non-irritating and non-sensitizing keratolytic proteases should be used and used in adequate doses, ie 0.1 to 20 Units / g of finished cosmetic product, preferably between 1 and 10 Units / g.

Les substances inhibitrices de la mélanogénèse (inhibiteurs de tyrosinase, inhibiteurs de glycosylation etc.) sont employées dans les doses habituelles; par exemple, I'acide gluconique et la glucosamine s'emploient entre 0.01 et 10%, préférentiellement entre 0.1 et 5% dans le produit cosmétique fini, les dérivés précurseurs ou analogues de vitamine A sont utilisés entre 0,00001 et 0,01 %.Substances that inhibit melanogenesis (tyrosinase inhibitors, glycosylation inhibitors, etc.) are used in the usual doses; for example, gluconic acid and glucosamine are used between 0.01 and 10%, preferably between 0.1 and 5% in the finished cosmetic product, precursor derivatives or vitamin A analogues are used between 0.00001 and 0.01% .

La combinaison des kératinases/protéases avec les substances dépigrnentantes simples ou complexes peut être utilisée dans toute forme de produit cosmétique destiné à éclaircir la peau à savoir, les émulsions E/H, hilE, les laits, butions, les gels, les pommades, les shampooings et les produits de traitement du cuir chevelu, les produits de maquillage. Pour l'utilisation dans les produits finis, ces combinaisons peuvent être présentées sous forme de dispersion aqueuse, de pâte, de poudre, de baume, d'huile. Ils peuvent être avantageusement inclus dans des vecteurs cosmétiques tels que les liposomes, les chylomicrons, les micro- ou nanoparScules, les micro- ou nanocasules. Ils peuvent être absorbés sur des supports poreux comme les microéponges, les silicates, bentonites, talcs, polyamides ou polyacrylates.The combination of keratinases / proteases with simple or complex depigmenting substances can be used in any form of cosmetic product intended to lighten the skin, namely W / O emulsions, hilE, milks, preparations, gels, ointments, shampoos and scalp treatment products, makeup products. For use in finished products, these combinations can be presented as an aqueous dispersion, paste, powder, balm, oil. They can advantageously be included in cosmetic vectors such as liposomes, chylomicrons, micro- or nanoparticles, micro- or nanocasules. They can be absorbed on porous substrates such as micro sponges, silicates, bentonites, talcs, polyamides or polyacrylates.

Par ailleurs, les protéases peuvent être de toute origine, préférentiellement d'origine végétale ou biotechnologique, et peuvent être employées sous forme de poudre, de solution, de dispersion; elles peuvent être stabilisées par les moyens connus de l'homme de l'art (encapsulat on,adsorption, modification chimique etc.). Furthermore, the proteases may be of any origin, preferably of plant or biotechnological origin, and may be used in the form of powder, solution or dispersion; they can be stabilized by means known to those skilled in the art (encapsulation, adsorption, chemical modification etc.).

Claims (7)

REVENDICATIONS 1) Compositions cosmétiques contenant au moins une substance1) Cosmetic compositions containing at least one substance possédant une activité de dépigmentation cutanée et des protéases kératolytiques.  possessing skin depigmentation activity and keratolytic proteases. 2) Compositions cosmétiques selon la revendication 1 caractérisées2) Cosmetic compositions according to claim 1 characterized en ce que les protéases sont d'origine végétale ou biotechnologique. in that the proteases are of vegetable or biotechnological origin. 3) Compositions cosmétiques selon les revendications 1 et 23) Cosmetic compositions according to claims 1 and 2 caractérisées en ce qu'elles contiennent comme substance characterized in that they contain as substance d'éclaircissement de la peau une ou plusieurs substances choisies skin lightening one or more selected substances parmi l'acide gluconique, la glucosamine, le sel calcique de l'acide among gluconic acid, glucosamine, the calcium salt of the acid pantothène sulfonique, un dérivé analogue ou précurseur de la pantothenesulfonic acid, a similar derivative or precursor of vitamine A, préférentiellement le B carotène. vitamin A, preferentially B carotene. 4) Compositions cosmétiques selon les revendications 1 à 34) Cosmetic compositions according to claims 1 to 3 caractérisées en ce que protéases kératolytiques et les substances characterized in that keratolytic proteases and substances à activité dépigmentante sont utilisées sous forme de poudre, de depigmenting activity are used in the form of powder, pâte, de dispersion aqueuse, de baume ou d'huile. paste, aqueous dispersion, balm or oil. 5) Compositions cosmétiques selon les revendications 1 à 45) Cosmetic compositions according to claims 1 to 4 caractérisées en ce que les protéases kératolytiques sont utilisées à characterized in that the keratolytic proteases are used at des doses comprises entre 0.1 Unités/g et 20 Unités/g de produit doses between 0.1 Units / g and 20 Units / g of product cosmétique fini, préférentiellement entre 1 et 10 unités/g. finished cosmetics, preferably between 1 and 10 units / g. 6) Compositions cosmétiques selon les revendications 1 à 56) Cosmetic compositions according to claims 1 to 5 caractérisées en ce qu'ils représentent toute forme de produit characterized in that they represent any form of product cosmétique, à savoir les émulsions H, H/E, les laits, lotions, les cosmetics, namely the emulsions H, H / E, the milks, lotions, gels, les pommades, les shampooings et les produits de traitement gels, ointments, shampoos and treatment products du cuir chevelu, les produits de maquillage.  scalp, make-up products. 7) Compositions cosmétiques selon les revendications 1 à 67) Cosmetic compositions according to claims 1 to 6 caractérisées en ce que les substances dépigmentantes et(ou les characterized in that the depigmenting substances and (or protéases kératolytiques peuvent être incluses dans des vecteurs Keratolytic proteases can be included in vectors cosmétiques tels les liposomes, les chylomicrons, les micro- ou cosmetics such as liposomes, chylomicrons, micro- nanoparticules, les micro- ou nanocapsules ou qu'ils peuvent être nanoparticles, micro- or nanocapsules or that they can be absorbés sur des supports poreux comme les microéponges, les absorbed on porous substrates such as micro sponges, silicates, bentonites, talcs, polyamides ou polyacrylates.  silicates, bentonites, talcs, polyamides or polyacrylates.
FR9503760A 1995-03-28 1995-03-28 NEW DEPIGMENTING COSMETIC COMPOSITIONS Expired - Fee Related FR2732215B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9503760A FR2732215B1 (en) 1995-03-28 1995-03-28 NEW DEPIGMENTING COSMETIC COMPOSITIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503760A FR2732215B1 (en) 1995-03-28 1995-03-28 NEW DEPIGMENTING COSMETIC COMPOSITIONS

Publications (2)

Publication Number Publication Date
FR2732215A1 true FR2732215A1 (en) 1996-10-04
FR2732215B1 FR2732215B1 (en) 1997-04-30

Family

ID=9477588

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9503760A Expired - Fee Related FR2732215B1 (en) 1995-03-28 1995-03-28 NEW DEPIGMENTING COSMETIC COMPOSITIONS

Country Status (1)

Country Link
FR (1) FR2732215B1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083031A2 (en) * 2000-05-01 2001-11-08 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
EP1384482A1 (en) * 2001-03-27 2004-01-28 Kanebo, Limited External skin compositions
FR2852828A1 (en) * 2003-03-25 2004-10-01 Oreal COMPOSITION FOR TREATING KERATINIC MATERIALS COMPRISING A HYDROXYCARBOXYLIC ACID AND A PROTECTIVE AGENT OR CONDITIONER
WO2010067327A1 (en) 2008-12-11 2010-06-17 Sederma Cosmetic composition containing acetylated oligoglucuronans
WO2010082177A2 (en) 2009-01-16 2010-07-22 Sederma New compounds, in particular peptides, compositions comprising them and cosmetic and dermopharmaceutical uses
WO2010082175A2 (en) 2009-01-16 2010-07-22 Sederma New compounds, in particular peptides, compositions comprising them and cosmetic and dermopharmaceutical uses
WO2010082176A2 (en) 2009-01-16 2010-07-22 Sederma Cosmetic composition containing kxk type peptides and uses
WO2010136965A2 (en) 2009-05-26 2010-12-02 Sederma Cosmetic use of tyr-arg dipeptide to combat cutaneous sa
EP2510982A1 (en) 2006-05-05 2012-10-17 Sederma Cosmetic compositions comprising at least one peptide with at least one immobilized aromatic cycle
US8361516B2 (en) 2006-08-03 2013-01-29 Sederma Composition comprising sarsasapogenin
US8404648B2 (en) 2006-02-16 2013-03-26 Sederma Polypeptides KXK and their use
US8741357B2 (en) 2005-01-14 2014-06-03 Sederma Sas Cosmetic or dermopharmaceutical composition comprising an euglena extract
US8846019B2 (en) 2005-09-06 2014-09-30 Sederma Use of protoberberines as an active substance regulating the pilosebaceous unit
US9050477B2 (en) 2009-04-17 2015-06-09 Sederma Cosmetic compositions comprising oridonin and new cosmetic uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749719A (en) * 1983-09-21 1988-06-07 Sogo Pharmaceutical Company Limited Method of treating skin pigmentation abnormalities with pantetheine-S-sulfonic acid
JPH01186811A (en) * 1988-01-20 1989-07-26 Sunstar Inc Skin beautifying cosmetic
WO1993013742A1 (en) * 1992-01-16 1993-07-22 Cosmetics Development Company Limited Preparation for skin use
WO1994027569A1 (en) * 1993-06-01 1994-12-08 Dermatology Home Products, Inc. Skin treatment method utilizing a composition and a pad
WO1995007686A1 (en) * 1993-09-15 1995-03-23 Unilever Plc Skin care composition comprising thiol proteases from the stratum corneum

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749719A (en) * 1983-09-21 1988-06-07 Sogo Pharmaceutical Company Limited Method of treating skin pigmentation abnormalities with pantetheine-S-sulfonic acid
JPH01186811A (en) * 1988-01-20 1989-07-26 Sunstar Inc Skin beautifying cosmetic
WO1993013742A1 (en) * 1992-01-16 1993-07-22 Cosmetics Development Company Limited Preparation for skin use
WO1994027569A1 (en) * 1993-06-01 1994-12-08 Dermatology Home Products, Inc. Skin treatment method utilizing a composition and a pad
WO1995007686A1 (en) * 1993-09-15 1995-03-23 Unilever Plc Skin care composition comprising thiol proteases from the stratum corneum

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 112, no. 20, 14 May 1990, Columbus, Ohio, US; abstract no. 185579, H. ANDO: "Skin-lightening cosmetics containing unsaturated fatty acids" *
N. TANAKA: "Effect and Action of Enzymes on Skin", COSMETICS & TOILETRIES, vol. 96, pages 37 - 40 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083031A3 (en) * 2000-05-01 2002-04-11 Bioderm Inc Topical composition for the treatment of psoriasis and related skin disorders
AU2001259311B2 (en) * 2000-05-01 2005-12-08 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US7670620B2 (en) 2000-05-01 2010-03-02 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
WO2001083031A2 (en) * 2000-05-01 2001-11-08 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
EP1384482A1 (en) * 2001-03-27 2004-01-28 Kanebo, Limited External skin compositions
EP1384482A4 (en) * 2001-03-27 2004-06-30 Kanebo Ltd External skin compositions
FR2852828A1 (en) * 2003-03-25 2004-10-01 Oreal COMPOSITION FOR TREATING KERATINIC MATERIALS COMPRISING A HYDROXYCARBOXYLIC ACID AND A PROTECTIVE AGENT OR CONDITIONER
US8741357B2 (en) 2005-01-14 2014-06-03 Sederma Sas Cosmetic or dermopharmaceutical composition comprising an euglena extract
US8846019B2 (en) 2005-09-06 2014-09-30 Sederma Use of protoberberines as an active substance regulating the pilosebaceous unit
US8404648B2 (en) 2006-02-16 2013-03-26 Sederma Polypeptides KXK and their use
US8507649B2 (en) 2006-05-05 2013-08-13 Sederma Cosmetic compositions comprising at least one peptide with at least one immobilized aromatic cycle
EP2510982A1 (en) 2006-05-05 2012-10-17 Sederma Cosmetic compositions comprising at least one peptide with at least one immobilized aromatic cycle
US8361516B2 (en) 2006-08-03 2013-01-29 Sederma Composition comprising sarsasapogenin
WO2010067327A1 (en) 2008-12-11 2010-06-17 Sederma Cosmetic composition containing acetylated oligoglucuronans
WO2010082176A2 (en) 2009-01-16 2010-07-22 Sederma Cosmetic composition containing kxk type peptides and uses
WO2010082175A2 (en) 2009-01-16 2010-07-22 Sederma New compounds, in particular peptides, compositions comprising them and cosmetic and dermopharmaceutical uses
US8697656B2 (en) 2009-01-16 2014-04-15 Sederma Compounds, in particular peptides, compositions comprising them and cosmetic and dermo-pharmaceutical uses
WO2010082177A2 (en) 2009-01-16 2010-07-22 Sederma New compounds, in particular peptides, compositions comprising them and cosmetic and dermopharmaceutical uses
EP3744729A1 (en) 2009-01-16 2020-12-02 Sederma Compounds, in particular peptides, compositions comprising them and cosmetic and dermopharmaceutical uses
US9050477B2 (en) 2009-04-17 2015-06-09 Sederma Cosmetic compositions comprising oridonin and new cosmetic uses
WO2010136965A2 (en) 2009-05-26 2010-12-02 Sederma Cosmetic use of tyr-arg dipeptide to combat cutaneous sa

Also Published As

Publication number Publication date
FR2732215B1 (en) 1997-04-30

Similar Documents

Publication Publication Date Title
CA2044269C (en) Cafeic acid based pharmaceutical and cosmetic depigmenting compositions
EP0623342B1 (en) Use of an alkyl ester of glutathione in a cosmetic or dermatological composition for the topical treatment of skin ageing
FR2732215A1 (en) Skin-lightening cosmetic compsns.
EP2109440B1 (en) Association of compounds inhibiting melanogenesis and use thereof in cosmetics and dermatology
CH653569A5 (en) EMULSIFYING SYSTEM BASED ON FATTY ACID OR CONDENSATE OF PROTEINS, POLYOXYETHYLENE STEROL AND PHOSPHATIDE AND COSMETIC OR PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
FR2751874A1 (en) NEW COSMETIC COMPOSITIONS TO ENHANCE AND BRIGHTEN SKIN
EP1278532B1 (en) Plant extract of the olea europaea species as no-synthase inhibitor and uses
JP4393064B2 (en) How to use tyramine as a cosmetic ingredient to make white skin
FR2582306A1 (en) N-ACYL-THIAZOLIDINE-4-CARBOXYLIC ACID SALTS AND 6-PIPERIDINO-2,4-DIAMINOPYRIMIDINE-3-OXIDE AND COSMETIC-DERMATOLOGICAL COMPOSITIONS CONTAINING SAME
CH706226B1 (en) Preparation for skin lightening.
EP0713696B1 (en) Topical application product containing a lipase and a precursor of hydroxyacid
EP0820763B1 (en) Use of N,N&#39;-dibenzyl-ethylene diamine acid derivatives as depigmentation agents
FR2791255A1 (en) Anti-androgenic compositions contain a vegetable-based complex derived from sabal, marrow and epilobium, for prevention of hair regrowth, loss of hair, and seborrhea
FR2641696A2 (en) Use of a mixture containing lactoferrin in cosmetic anti-free-radical preparations
FR2799645A1 (en) USE OF DHEA OR ITS PRECURSORS OR METABOLIC DERIVATIVES AS DEPIGMENTANT
EP1566168B1 (en) Dermo-cosmetic compositions for depigmenting and use of it
FR2590169A1 (en) Cosmetic composition containing biostimulins
JP2007537218A (en) Dermatological composition for treating skin pigmentation
FR3068244B1 (en) DEPIGMENTING COMPOUNDS
FR2788693A1 (en) Use of unfermented honey as an agent for depigmenting and/or lightening the skin, body hair or head hair and/or for treating liver spots
CN1189157C (en) Natural activated additive for cosmetics to remove spots and beautify face
FR2811566A1 (en) COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND / OR ITS PRECURSORS OR DERIVATIVES, AND A VITAMIN
FR3082121A1 (en) NEW COMPLEX OF DEPIGMENTING ASSETS
FR2847467A1 (en) Cosmetic compositions, e.g. for combating skin barrier function deficiency, dryness or aging symptoms, contain modulator of oxysterol 7 alpha-hydroxylase activity, e.g. dexamethasone
FR2761604A1 (en) NEW COSMETIC COMPOSITIONS TO ENHANCE AND BRIGHTEN SKIN

Legal Events

Date Code Title Description
ST Notification of lapse